KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Accured Expenses (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Change in Accured Expenses data on record, last reported at $249.6 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 100.96% year-over-year to $249.6 million; the TTM value through Dec 2025 reached $104.3 million, down 5.77%, while the annual FY2025 figure was $104.3 million, 5.77% down from the prior year.
  • Change in Accured Expenses reached $249.6 million in Q4 2025 per SRPT's latest filing, up from -$103.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $249.6 million in Q4 2025 and bottomed at -$103.2 million in Q3 2025.
  • Average Change in Accured Expenses over 5 years is $16.8 million, with a median of -$1.7 million recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: soared 396.97% in 2024, then tumbled 6223.03% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $69.8 million in 2021, then crashed by 81.55% to $12.9 million in 2022, then skyrocketed by 374.36% to $61.1 million in 2023, then skyrocketed by 103.34% to $124.2 million in 2024, then surged by 100.96% to $249.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $249.6 million in Q4 2025, -$103.2 million in Q3 2025, and -$24.5 million in Q2 2025.